Publication date: Feb 15, 2025
Anti-tuberculosis drug-induced liver injury (ATLI) is a significant adverse drug reaction with genetic susceptibility implications. This study aimed to integrate findings from systematic reviews and meta-analyses on genetic polymorphisms associated with ATLI risk, enhance evidence synthesis, and identify susceptibility gene polymorphisms linked to ATLI occurrence. The protocol was registered in PROSPERO (CRD42024517311). Systematic searches of PubMed, EMBASE, Web of Science, and Cochrane Library databases were conducted to identify eligible studies from inception to February 21, 2024. Two authors independently reviewed eligibility, extracted data, and assessed quality. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate associations between genetic polymorphisms and ATLI susceptibility. A total of 25 meta-analyses were included, including 57 single nucleotide polymorphisms (SNPs) in 15 candidate genes. Significant associations were found for the glutathione S-transferase M1 (GSTM1) null genotype (OR = 1. 43, 95% CI: 1. 18-1. 73, P
| Concepts | Keywords |
|---|---|
| Crd42024517311 | Genetic polymorphisms |
| Genetic | NAT2 |
| Library | Umbrella review |
| Liver | |
| Tuberculosis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | adverse drug reaction |
| disease | IDO | susceptibility |
| disease | IDO | quality |